Apellis Pharmaceuticals, Inc. (APLS)

Apellis Pharmaceuticals Revenue by Segment

Period Ending	Mar 31, 2025	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021
Product	696.78M	709.95M	657.44M	580.05M	490.56M	366.28M	247.28M	165.77M
Product Growth	42.04%	93.83%	165.87%	249.90%	434.47%	462.71%	352.49%	292.02%
Collaboration License and Other	79.06M	71.41M	57.78M	48.74M	33.51M	30.31M	25.60M	18.76M
Collaboration License and Other Growth	135.91%	135.62%	125.73%	159.80%	137.61%	193.41%	-56.17%	-65.49%

Product Revenue by Segment

Period Ending	Mar 31, 2025	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021
Syfovre	604.58M	611.85M	558.35M	481.67M	394.39M	275.28M	160.98M	85.70M
Syfovre Growth	53.30%	122.26%	246.84%	462.03%	2,048.08%	-	-	-
Empaveli	92.22M	98.13M	99.13M	98.42M	96.21M	91.04M	86.34M	80.14M
Empaveli Growth	-4.15%	7.79%	14.81%	22.81%	30.91%	39.72%	57.93%	89.58%

Source: Business metrics provided by Main Street Data and sourced from official company press releases and documents.